Relative risk of late mortality among 2-year survivors of allogeneic hematopoietic cell transplantation
| Variables . | Death from any cause . | Relapse-related mortality . | Nonrelapse-related mortality . | |||
|---|---|---|---|---|---|---|
| Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | |
| Age at transplantation, y | ||||||
| Younger than 18 | 1.0 | — | 1.0 | — | 1.0 | — |
| 18 to 45 y | 1.31 (0.91-1.89) | .1 | 0.89 (0.49-1.64) | .7 | 1.72 (1.08-2.73) | .02 |
| Older than 45 y | 2.56 (1.51-4.35) | .001 | 1.43 (0.48-4.24) | .5 | 3.71 (1.97-6.98) | <.001 |
| Year of transplantation | ||||||
| 1974 to 1979 | 1.0 | — | 1.0 | — | 1.0 | — |
| 1980 to 1984 | 0.70 (0.35-1.39) | .3 | 0.33 (0.11-0.98) | .05 | 0.90 (0.37-2.23) | .8 |
| 1985 to 1989 | 0.67 (0.32-1.41) | .3 | 0.25 (0.08-0.81) | .02 | 0.95 (0.36-2.51) | .9 |
| 1990 to 1994 | 0.71 (0.33-1.55) | .4 | 0.31 (0.09-1.07) | .06 | 0.98 (0.36-2.71) | .999 |
| 1995 to 1998 | 0.60 (0.26-1.38) | .2 | 0.22 (0.06-0.88) | .03 | 0.87 (0.30-2.54) | .8 |
| Sex | ||||||
| Male | 1.0 | — | 1.0 | — | 1.0 | — |
| Female | 0.91 (0.70-1.20) | .5 | 0.97 (0.58-1.63) | .9 | 0.89 (0.64-1.22) | .5 |
| Donor type | ||||||
| Sibling | 1.0 | — | 1.0 | — | 1.0 | — |
| Unrelated | 1.39 (0.89-2.17) | .1 | 1.09 (0.47-2.51) | .8 | 1.60 (0.94-2.71) | .08 |
| Risk of relapse at HCT | ||||||
| Standard risk | 1.0 | — | 1.0 | — | 1.0 | — |
| High risk | 1.69 (1.25-2.27) | .001 | 3.69 (2.18-6.23) | <.001 | 1.23 (0.85-1.78) | .3 |
| Race | ||||||
| White | 1.0 | — | 1.0 | — | 1.0 | — |
| Hispanic | 0.77 (0.51-1.15) | .2 | 0.84 (0.37-1.88) | .7 | 0.71 (0.44-1.12) | .1 |
| Other | 1.10 (0.68-1.77) | .7 | 2.23 (1.07-4.65) | .03 | 0.77 (0.41-1.44) | .4 |
| CGVHD | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 2.26 (1.67-3.06) | <.001 | 1.70 (0.96-2.99) | .1 | 2.68 (1.85-3.87) | <.001 |
| Diagnosis | ||||||
| CML | 1.0 | — | 1.0 | — | 1.0 | — |
| AML | 1.18 (0.83-1.67) | .4 | 0.79 (0.40-1.55) | .5 | 1.45 (0.96-2.19) | .08 |
| NHL | 1.22 (0.59-2.51) | .6 | 0.59 (0.11-3.07) | .5 | 1.47 (0.65-3.34) | .4 |
| SAA | 0.45 (0.17-1.18) | .1 | — | — | 0.79 (0.28-2.25) | .7 |
| ALL | 1.16 (0.76-1.76) | .5 | 1.34 (0.66-2.73) | .4 | 1.03 (0.60-1.75) | .9 |
| IEM | 1.56 (0.67-3.62) | .3 | 1.21 (0.24-6.03) | .8 | 1.83 (0.67-4.98) | .2 |
| Conditioning | ||||||
| Cyclophosphamide | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.10 (0.70-1.72) | .7 | 0.79 (0.35-1.78) | .6 | 1.16 (0.67-2.02) | .6 |
| TBI | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.62 (0.27-1.44) | .3 | 0.16 (0.01-3.03) | .2 | 0.66 (0.26-1.68) | .4 |
| Etoposide | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.27 (0.77-2.08) | .3 | 0.77 (0.31-1.91) | .6 | 1.50 (0.83-2.73) | .2 |
| Busulfan | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.66 (0.28-1.55) | .3 | 0.14 (0.01-2.68) | .2 | 0.84 (0.33-2.16) | .7 |
| Cytarabine | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.29 (0.71-2.34) | .4 | 0.99 (0.36-2.74) | .999 | 1.44 (0.69-3.02) | .3 |
| Graft-versus-host disease prophylaxis | ||||||
| Methotrexate | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.55 (0.38-0.81) | .003 | 0.59 (0.27-1.30) | .2 | 0.52 (0.33-0.82) | .005 |
| CSA | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.68 (0.45-1.04) | .1 | 0.58 (0.27-1.25) | .2 | 0.70 (0.43-1.16) | .2 |
| Prednisone | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.07 (0.79-1.45) | .7 | 0.81 (0.46-1.41) | .4 | 1.17 (0.81-1.69) | .4 |
| T-cell depletion | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.73 (0.37-1.44) | .4 | 1.16 (0.37-3.71) | .8 | 0.55 (0.23-1.33) | .2 |
| Variables . | Death from any cause . | Relapse-related mortality . | Nonrelapse-related mortality . | |||
|---|---|---|---|---|---|---|
| Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | |
| Age at transplantation, y | ||||||
| Younger than 18 | 1.0 | — | 1.0 | — | 1.0 | — |
| 18 to 45 y | 1.31 (0.91-1.89) | .1 | 0.89 (0.49-1.64) | .7 | 1.72 (1.08-2.73) | .02 |
| Older than 45 y | 2.56 (1.51-4.35) | .001 | 1.43 (0.48-4.24) | .5 | 3.71 (1.97-6.98) | <.001 |
| Year of transplantation | ||||||
| 1974 to 1979 | 1.0 | — | 1.0 | — | 1.0 | — |
| 1980 to 1984 | 0.70 (0.35-1.39) | .3 | 0.33 (0.11-0.98) | .05 | 0.90 (0.37-2.23) | .8 |
| 1985 to 1989 | 0.67 (0.32-1.41) | .3 | 0.25 (0.08-0.81) | .02 | 0.95 (0.36-2.51) | .9 |
| 1990 to 1994 | 0.71 (0.33-1.55) | .4 | 0.31 (0.09-1.07) | .06 | 0.98 (0.36-2.71) | .999 |
| 1995 to 1998 | 0.60 (0.26-1.38) | .2 | 0.22 (0.06-0.88) | .03 | 0.87 (0.30-2.54) | .8 |
| Sex | ||||||
| Male | 1.0 | — | 1.0 | — | 1.0 | — |
| Female | 0.91 (0.70-1.20) | .5 | 0.97 (0.58-1.63) | .9 | 0.89 (0.64-1.22) | .5 |
| Donor type | ||||||
| Sibling | 1.0 | — | 1.0 | — | 1.0 | — |
| Unrelated | 1.39 (0.89-2.17) | .1 | 1.09 (0.47-2.51) | .8 | 1.60 (0.94-2.71) | .08 |
| Risk of relapse at HCT | ||||||
| Standard risk | 1.0 | — | 1.0 | — | 1.0 | — |
| High risk | 1.69 (1.25-2.27) | .001 | 3.69 (2.18-6.23) | <.001 | 1.23 (0.85-1.78) | .3 |
| Race | ||||||
| White | 1.0 | — | 1.0 | — | 1.0 | — |
| Hispanic | 0.77 (0.51-1.15) | .2 | 0.84 (0.37-1.88) | .7 | 0.71 (0.44-1.12) | .1 |
| Other | 1.10 (0.68-1.77) | .7 | 2.23 (1.07-4.65) | .03 | 0.77 (0.41-1.44) | .4 |
| CGVHD | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 2.26 (1.67-3.06) | <.001 | 1.70 (0.96-2.99) | .1 | 2.68 (1.85-3.87) | <.001 |
| Diagnosis | ||||||
| CML | 1.0 | — | 1.0 | — | 1.0 | — |
| AML | 1.18 (0.83-1.67) | .4 | 0.79 (0.40-1.55) | .5 | 1.45 (0.96-2.19) | .08 |
| NHL | 1.22 (0.59-2.51) | .6 | 0.59 (0.11-3.07) | .5 | 1.47 (0.65-3.34) | .4 |
| SAA | 0.45 (0.17-1.18) | .1 | — | — | 0.79 (0.28-2.25) | .7 |
| ALL | 1.16 (0.76-1.76) | .5 | 1.34 (0.66-2.73) | .4 | 1.03 (0.60-1.75) | .9 |
| IEM | 1.56 (0.67-3.62) | .3 | 1.21 (0.24-6.03) | .8 | 1.83 (0.67-4.98) | .2 |
| Conditioning | ||||||
| Cyclophosphamide | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.10 (0.70-1.72) | .7 | 0.79 (0.35-1.78) | .6 | 1.16 (0.67-2.02) | .6 |
| TBI | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.62 (0.27-1.44) | .3 | 0.16 (0.01-3.03) | .2 | 0.66 (0.26-1.68) | .4 |
| Etoposide | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.27 (0.77-2.08) | .3 | 0.77 (0.31-1.91) | .6 | 1.50 (0.83-2.73) | .2 |
| Busulfan | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.66 (0.28-1.55) | .3 | 0.14 (0.01-2.68) | .2 | 0.84 (0.33-2.16) | .7 |
| Cytarabine | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.29 (0.71-2.34) | .4 | 0.99 (0.36-2.74) | .999 | 1.44 (0.69-3.02) | .3 |
| Graft-versus-host disease prophylaxis | ||||||
| Methotrexate | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.55 (0.38-0.81) | .003 | 0.59 (0.27-1.30) | .2 | 0.52 (0.33-0.82) | .005 |
| CSA | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.68 (0.45-1.04) | .1 | 0.58 (0.27-1.25) | .2 | 0.70 (0.43-1.16) | .2 |
| Prednisone | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 1.07 (0.79-1.45) | .7 | 0.81 (0.46-1.41) | .4 | 1.17 (0.81-1.69) | .4 |
| T-cell depletion | ||||||
| No | 1.0 | — | 1.0 | — | 1.0 | — |
| Yes | 0.73 (0.37-1.44) | .4 | 1.16 (0.37-3.71) | .8 | 0.55 (0.23-1.33) | .2 |
— indicates not applicable.